Cambridge Epigenetix (CEGX) is a rapidly growing company focused on developing innovative methods and technologies to revolutionise the fields of epigenetics and personalised medicine.
In October 2014 it completed a $5.5M Series A financing led by New Science Ventures. GV – formerly Google Ventures – led a $21 million Series B funding round in March 2016 with significant participation from Sequoia Capital. Current investors New Science Ventures, Syncona Partners and Cambridge University also joined the round.
Ahren Innovation Capital led a $30 million Series C funding round in 2018 with strong participation from existing investors.
Professor Shankar Balasubramanian of the University of Cambridge’s Department of Chemistry founded CEGX in 2012 to develop innovative epigenetic research tools that could identify, decode and help elucidate the function of the ‘extra’ DNA bases.
Prior to launching Cambridge Epigenetix, Professor Balasubramanian co-founded DNA sequencing pioneer Solexa which was acquired by Illumina in 2007.
In 2013, CEGX launched the TrueMethyl™ kit, allowing researchers to access ox-BS sequencing for the first time. The TrueMethyl kit is now in use in labs around the world and has already formed the technological backbone of several breakthrough epigenetic papers.